ClinicalTrials.Veeva

Menu

Pharmacokinetics of Levosimendan in Pediatric Intensive Care Units (PALMAréa)

N

Nantes University Hospital (NUH)

Status

Completed

Conditions

Acute Heart Failure

Study type

Observational

Funder types

Other

Identifiers

NCT03681379
RC16_0114

Details and patient eligibility

About

To describe pharmacokinetics of levosimendan in neonates and children supported or not with extracorporeal circulation devices (ECMO, CRRT)

Full description

Levosimendan is a calcium sensitiver wih inotropic effects. It's use in the context of acute or chronic heart failure in children has yet to be defined. Due to physical proprieties of levosimendan and metabolites, we hypothesized that concomitant use of extracorporeal devices such as ECMO will cause major pharmacokinetic variations. Furthermore, pharmacokinetics of levosimendan in children with multiple organ failure has to be specify.

Enrollment

27 patients

Sex

All

Ages

Under 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All children admitted in pediatric intensive care units with planned infusion of 0.2 mcg/kg/min of levosimendan over 24h in context of routine care
  • Arterial line or central venous catheter inserted for blood sampling procedures in context of routine care.

Exclusion criteria

  • Absence of clear parental status or information

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems